Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with cutaneous T-cell lymphoma

Scritto il 20/01/2026
da Isabelle Krämer

No abstract

Bone Marrow Transplant. 2026 Jan 20. doi: 10.1038/s41409-025-02796-8. Online ahead of print.

NO ABSTRACT

PMID:41559396 | DOI:10.1038/s41409-025-02796-8